G6PD activator AG1 是一种有效的选择性 6-磷酸葡萄糖脱氢酶 (G6PD) 激动剂，EC₅₀ 为 3 µΜ。G6PD activator AG1 可以减少人红细胞的溶血。

G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) activator with an EC 50 of 3 μΜ. G6PD activator AG1 reduces hemolysis of human erythrocytes.

Oil

IC50: 3 μΜ (G6PD)

AG1 (50, 100, 250, 500, 750, 1000?nM) of 1?μM increases the viability by 20% and the proteolytic stability of Canton G6PD in SH-SY5Y cells. AG1 has no effect when G6PD was knocked down by siRNA, supporting the specificity of AG1 toward G6PD.
AG1 (1-5?μΜ; pre-incubated overnight) reduces the extent of hemolysis with 5 μΜ in human erythrocytes suspension (5%) exposed to either 1?mM chloroquine (CQ; 4 hours) or diamide (a GSH oxidant; 4 hours). AG1 increases GSH levels and reduced ROS levels together with increased G6PD activity under these drug-induced oxidative stress.
AG1 has no effect on the dimerization or activity of several other NAD- or NADP+-dependent dimeric or tetrameric enzymes, including 6-phosphogluconate dehydrogenase (6PGD), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), aldehyde dehydrogenase 2 (ALDH2), and aldehyde dehydrogenase 3A1 (ALDH3A1).

Room temperature in continental US; may vary elsewhere.

4°C, protect from light 该产品在溶液状态不稳定，建议您现用现配，即刻使用。

[1]. https://patents.google.com/patent/WO2019023264A1/en?oq=WO2019023264A1
[2]. Kaitlyn Ryan, et al. Current investigations on clinical pharmacology and therapeutics of Glucose-6-phosphate dehydrogenase deficiency. Pharmacol Ther. 2020 Dec 14;222:107788.

In Vitro: DMSO : 20.83 mg/mL (47.49 mM; Need ultrasonic)配制储备液